Regulatory News:
Vitrolife (STO:VITR) has appointed a new management team in order to further strengthen the company's future expansion and competitiveness.
Vitrolife announced on July 10 that Maria Forss has been appointed in a new role as Vice President Business Development and Global Marketing. As from October 1, Vitrolife's new management team will consist of Maria Forss, Emma Sjöqvist COO, Christer Silversand CSO, Mikael Engblom CFO and Thomas Axelsson, CEO. No Vice President has been appointed in the Parent Company.
"With the latest addition of Maria Forss, Vitrolife has established a very broad and competent management team that covers the company's key areas, and I believe it will create substantial value for Vitrolife's customers and shareholders," says Thomas Axelsson, CEO.
July 12, 2012
Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson
CEO
Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.
Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 12, 2012 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://www.cisionwire.com
Contacts:
Thomas Axelsson, CEO, phone 46 31 721 80 01
or
Mikael Engblom,
CFO, phone 46 31 721 80 14
